Ipamorelin is a pentapeptide agonist of the ghrelin receptor that stimulates growth hormone release with minimal elevation of cortisol, prolactin, and ACTH compared with other members of its family. Any discussion of ipamorelin benefits starts there. That selectivity is the compound's defining feature, and it is documented in pituitary secretion studies.
What it is and where it comes from
Ipamorelin is a five-amino-acid molecule developed as an agonist of the growth hormone secretagogue receptor, the same receptor ghrelin activates.
It was designed specifically for selectivity: to obtain the stimulus on GH release without dragging along the effects on other hormonal axes that characterized the earlier GHRPs.
Selectivity compared with GHRP-2 and GHRP-6
This is the compound's central point, and it pays to be precise about what it means.
GHRPs act on the pituitary, which produces several hormones besides GH. The less selective members of the family also stimulate the release of ACTH, which in turn raises cortisol, and of prolactin.
What the secretion studies describe:
| Compound | GH stimulus | Cortisol / ACTH | Prolactin | Appetite |
|---|---|---|---|---|
| Ipamorelin | Marked | Minimal | Minimal | Minimal |
| GHRP-2 | Marked | Appreciable rise | Appreciable rise | Moderate |
| GHRP-6 | Marked | Appreciable rise | Appreciable rise | Marked |
| Hexarelin | Very marked | Appreciable rise | Appreciable rise | Moderate |
Selectivity is a matter of degree, not all or nothing. "Minimal" does not mean zero. It means that in the comparative studies the rise did not reach the magnitude seen with the other agents.
One methodological note belongs here: these data come from acute secretion studies, meaning what happens to hormone concentrations after a dose. They are markers. What happens under repeated stimulation over months is far less characterized.
Why it barely affects appetite
That ipamorelin does not produce the marked hunger typical of GHRP-6 looks counterintuitive at first. Both act on the ghrelin receptor, and ghrelin is the hunger signal.
The explanation the literature works with involves functional selectivity: different agonists at the same receptor can preferentially activate some intracellular signaling pathways over others, producing different effect profiles. It is a phenomenon described in the pharmacology of G protein-coupled receptors.
Stated honestly: the exact mechanism of that dissociation is not fully resolved. What is documented is the observation, the difference in appetite response between compounds of the same family, not a closed explanation. The contrast is developed in the article on GHRP-6.
Pulsatility and the overnight window
As a ghrelin receptor agonist, ipamorelin produces a pulse of release, not a sustained elevation. That aligns it with the physiological pattern described in the GH axis pillar.
The main pulse of endogenous GH occurs during deep sleep. Study protocols that have sought to line up with that pattern did so for a physiological reason: a stimulus that coincides with the window in which the axis is naturally active competes less with somatostatin tone.
Combining with GHRH: the rationale
Ipamorelin is a GHRP. It stimulates through its own pathway and lowers somatostatin tone. A GHRH analog stimulates through a different one.
Combining the two acts on three points of the system instead of one, and the secretion response documented in endocrine physiology is greater than that of either agent alone. That is the real synergy in this field, and it is explained in detail in the pillar.
What adds nothing is combining ipamorelin with another GHRP: they compete for the same receptor.
Batch analytical data are on its technical sheet.
Limits: what it does not do
A necessary section, because lists of ipamorelin benefits lean on a reputation as "the cleanest," and that tends to be read as "the most effective." They are not the same thing.
It does not supply growth hormone. It stimulates the release of your own. If pituitary reserve is depleted or the response of the axis is limited, the stimulus has a ceiling.
Selective does not mean free of effects. It means fewer effects on other axes than its comparators.
There are no clinical outcome trials. What exists are hormone secretion studies: how much GH rises after a dose. What that translates into in terms of meaningful functional change over the medium term has not been studied in controlled trials. Again, the distinction between marker and outcome.
It is not approved by any agency, and for athletes under federation rules it falls under section S2 of the anti-doping list.
What the evidence does not settle
- Effects of repeated stimulation over months: poorly characterized.
- Degree of desensitization with prolonged use.
- Doses with an established relationship between exposure and effect in humans.
- Any functional outcome: there are no controlled trials.
Frequently asked questions
Why is ipamorelin called "clean"?
Because in comparative secretion studies it produces a marked GH stimulus with minimal elevation of cortisol, ACTH, and prolactin, unlike other GHRPs. That is a relative comparison, not an absolute absence of effects.
Does it increase appetite?
Much less than GHRP-6, despite acting on the same receptor. The explanation is attributed to functional selectivity between signaling pathways, although the exact mechanism is not settled.
Can it be combined with GHRP-2?
It adds nothing. Both are GHRPs and they compete for the same receptor. The combination with a rationale behind it is with a GHRH analog, which acts through a different pathway.
Does it replace growth hormone?
No. It stimulates the release of your own, preserving the pulsatile pattern and the feedback of the axis. Exogenous GH supplies the hormone directly and works in another way.
References
- Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology, 1998;139(5):552–561. DOI: 10.1530/eje.0.1390552
- Bowers CY. Growth hormone-releasing peptide (GHRP). Cellular and Molecular Life Sciences, 1998;54(12):1316–1329. DOI: 10.1007/s000180050252
- Kojima M, et al. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature, 1999;402:656–660. DOI: 10.1038/45230
- Müller EE, et al. Neuroendocrine control of growth hormone secretion. Physiological Reviews, 1999;79(2):511–607. DOI: 10.1152/physrev.1999.79.2.511
Written by the Bionic Editorial Team. Last reviewed: August 2026.
How we work: our editorial policy and source hierarchy.
This content is strictly educational and does not constitute medical advice, diagnosis or a therapeutic recommendation. The compounds mentioned are research products (Research Use Only) and are not approved by INVIMA, FDA, EMA or ANSM for therapeutic use in humans. Any health-related decision should be made with a licensed medical professional.